ADN-507 — Overview and Key Information ADN-507 is a small-molecule investigational drug developed as a selective antagonist of the dopamine D3 receptor. It has been studied for potential therapeutic applications in neuropsychiatric and substance-use disorders where modulation of D3-mediated pathways may reduce drug-seeking behavior, craving, or certain dysregulated motivational states. Mechanism of action
Target: Dopamine D3 receptor (high affinity/selectivity vs D2). Pharmacology: By blocking D3 receptors in limbic brain regions (e.g., nucleus accumbens, ventral tegmental area), ADN-507 is intended to reduce dopaminergic signaling tied to reward, cue-induced reinstatement, and motivated drug-seeking without heavily affecting motor circuits mediated by D2 receptors.
Preclinical evidence
Behavioral models: In rodent models of addiction, selective D3 antagonists like ADN-507 have shown reductions in reinstatement of drug-seeking triggered by cues or stress, decreased self-administration of stimulants/opioids in some studies, and attenuated conditioned place preference. Safety signals: Preclinical toxicology typically assesses cardiovascular, central nervous system, and metabolic parameters; selective D3 compounds aim to minimize extrapyramidal side effects associated with D2 blockade. ADN-507
Clinical development and indications (investigational)
Primary focus: Treatment of substance-use disorders (e.g., cocaine, methamphetamine, opioid use disorder) and possibly adjunctive therapy for certain impulse-control or mood-related conditions. Trial phases: ADN-507 would progress through phase 1 (safety, pharmacokinetics, receptor occupancy), phase 2 (proof-of-concept efficacy in target population), and later phases if signals are favorable. Key clinical endpoints include reduction in relapse rates, craving scores, drug-negative urine screens, and safety/tolerability.
Pharmacokinetics and dosing (general considerations) ADN-507 — Overview and Key Information ADN-507 is
Administration: Oral dosing is typical for small-molecule D3 antagonists. ADME: Expected profiling includes oral bioavailability, CNS penetration (blood–brain barrier crossing), hepatic metabolism (CYP interactions screened), and an elimination half-life supporting once- or twice-daily dosing. Drug interactions: Potential interactions with other CNS-active agents and with drugs metabolized by shared hepatic enzymes should be evaluated.
Safety and adverse effects
Anticipated AEs: Insomnia, gastrointestinal upset, headaches, and potential mood or anxiety changes; extrapyramidal symptoms are expected to be less common than with nonselective D2 antagonists. Monitoring: Neuropsychiatric status, movement abnormalities, ECG (if any QT liability), and routine labs during clinical trials. Pharmacology: By blocking D3 receptors in limbic brain
Research and development considerations
Biomarkers: PET imaging with D3-selective radioligands can confirm target engagement and receptor occupancy, guiding dose selection. Patient selection: Enrolling individuals with moderate-to-severe substance-use disorders and assessing comorbid psychiatric conditions for safety and efficacy. Combination therapy: Potential pairing with behavioral interventions (e.g., CBT, contingency management) to enhance outcomes. Regulatory path: Demonstrating clinically meaningful reductions in relapse and sustained abstinence with acceptable safety will be critical for approval.